Andrew M Courtwright1, Severine Cao2, Isabelle Wood3, Hari R Mallidi4, Jared Kawasawa5, Anna Moniodis6,7, Julie Ng8, Souheil El-Chemaly9, Hilary J Goldberg9. 1. Division of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Medicine. 3. Clinical Laboratory Division, Tissue Typing Laboratory. 4. Lung Transplant Program, Division of Thoracic Surgery. 5. University of Washington, Seattle, Washington. 6. Stamford Hospital, Stamford, Connecticut; and. 7. Columbia University, New York, New York. 8. Division of Pulmonary and Critical Care Medicine, and. 9. Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
Rationale: There is significant variation in approach to pre-lung transplant donor-specific antibodies (DSA), with some centers declining to cross any DSA. We implemented a protocol for transplantation for candidates with pretransplant DSA so long as a prospective complement-dependent cytotoxicity crossmatch was negative, regardless of number, specificity, class, or mean fluorescence intensity. Objectives: To compare post-transplant outcomes including overall survival, chronic lung allograft dysfunction-free survival, antibody-mediated rejection, and acute cellular rejection in lung transplant recipients where pretransplant DSA was and was not present. Methods: This was a single-center retrospective cohort study. For recipients with pretransplant DSA, if the prospective complement-dependent cytotoxicity crossmatch was negative, the donor offer was accepted and plasmapheresis was performed within 24 hours of transplantation and continued until retrospective crossmatch results returned. Immunosuppression and post-transplant management were not otherwise modified. Results: Of the 203 included recipients, 18 (8.9%) had pretransplant DSA. The median DSA mean fluorescence intensity was 4,000 (interquartile range, 2,975-5,625; total range, 2,100-17,000). The median number of DSA present per patient was one (interquartile range, 1-2). The presence of pretransplant DSA was not associated with increased mortality (hazard ratio, 1.2; 95% confidence interval [CI], 0.4-3.4) or decreased chronic lung allograft dysfunction-free survival (hazard ratio, 1.1; 95% CI, 0.6-2.1). Recipients with pretransplant DSA were more likely to require prolonged mechanical ventilation (adjusted odds ratio, 7.0; 95% CI, 2.3-21.6) and to have antibody-mediated rejection requiring treatment (adjusted odds ratio, 7.5; 95% CI, 1.0-55.8).Conclusions: A protocol of accepting donor offers for lung transplant candidates with preformed, complement-dependent cytotoxicity crossmatch-negative DSA is associated with increased need for prolonged mechanical ventilation and antibody-mediated rejection without affecting short-term overall or chronic lung allograft dysfunction-free survival.
Rationale: There is significant variation in approach to pre-lung transplant donor-specific antibodies (DSA), with some centers declining to cross any DSA. We implemented a protocol for transplantation for candidates with pretransplant DSA so long as a prospective complement-dependent cytotoxicity crossmatch was negative, regardless of number, specificity, class, or mean fluorescence intensity. Objectives: To compare post-transplant outcomes including overall survival, chronic lung allograft dysfunction-free survival, antibody-mediated rejection, and acute cellular rejection in lung transplant recipients where pretransplant DSA was and was not present. Methods: This was a single-center retrospective cohort study. For recipients with pretransplant DSA, if the prospective complement-dependent cytotoxicity crossmatch was negative, the donor offer was accepted and plasmapheresis was performed within 24 hours of transplantation and continued until retrospective crossmatch results returned. Immunosuppression and post-transplant management were not otherwise modified. Results: Of the 203 included recipients, 18 (8.9%) had pretransplant DSA. The median DSA mean fluorescence intensity was 4,000 (interquartile range, 2,975-5,625; total range, 2,100-17,000). The median number of DSA present per patient was one (interquartile range, 1-2). The presence of pretransplant DSA was not associated with increased mortality (hazard ratio, 1.2; 95% confidence interval [CI], 0.4-3.4) or decreased chronic lung allograft dysfunction-free survival (hazard ratio, 1.1; 95% CI, 0.6-2.1). Recipients with pretransplant DSA were more likely to require prolonged mechanical ventilation (adjusted odds ratio, 7.0; 95% CI, 2.3-21.6) and to have antibody-mediated rejection requiring treatment (adjusted odds ratio, 7.5; 95% CI, 1.0-55.8).Conclusions: A protocol of accepting donor offers for lung transplant candidates with preformed, complement-dependent cytotoxicity crossmatch-negative DSA is associated with increased need for prolonged mechanical ventilation and antibody-mediated rejection without affecting short-term overall or chronic lung allograft dysfunction-free survival.
Authors: Marc Lúcia; Sergi Luque; Elena Crespo; Edoardo Melilli; Josep M Cruzado; Jaume Martorell; Marta Jarque; Salvador Gil-Vernet; Anna Manonelles; Josep M Grinyó; Oriol Bestard Journal: Kidney Int Date: 2015-07-15 Impact factor: 10.612
Authors: Laneshia K Tague; Chad A Witt; Derek E Byers; Roger D Yusen; Patrick R Aguilar; Hrishikesh S Kulkarni; Karen Bennett Bain; Keith A Fester; Varun Puri; Daniel Kreisel; Thalachallour Mohanakumar; Elbert P Trulock; Ramsey R Hachem Journal: Ann Am Thorac Soc Date: 2019-07
Authors: Sean Agbor-Enoh; Annette M Jackson; Ilker Tunc; Gerald J Berry; Adam Cochrane; David Grimm; Andrew Davis; Pali Shah; Anne W Brown; Yan Wang; Irina Timofte; Palak Shah; Sasha Gorham; Jennifer Wylie; Natalie Goodwin; Moon Kyoo Jang; Argit Marishta; Kenneth Bhatti; Ulgen Fideli; Yanqin Yang; Helen Luikart; Zeling Cao; Mehdi Pirooznia; Jun Zhu; Charles Marboe; Aldo Iacono; Steven D Nathan; Jonathan Orens; Hannah A Valantine; Kiran Khush Journal: J Heart Lung Transplant Date: 2018-01-31 Impact factor: 10.247
Authors: Jussi M Tikkanen; Lianne G Singer; S Joseph Kim; Yanhong Li; Matthew Binnie; Cecilia Chaparro; Chung-Wai Chow; Tereza Martinu; Sassan Azad; Shaf Keshavjee; Kathryn Tinckam Journal: Am J Respir Crit Care Med Date: 2016-09-01 Impact factor: 21.405
Authors: James P Bosanquet; Chad A Witt; Bradford C Bemiss; Derek E Byers; Roger D Yusen; Alexander G Patterson; Daniel Kreisel; Thalachallour Mohanakumar; Elbert P Trulock; Ramsey R Hachem Journal: J Heart Lung Transplant Date: 2015-06-10 Impact factor: 10.247
Authors: K J Tinckam; S Keshavjee; C Chaparro; D Barth; S Azad; M Binnie; C W Chow; M de Perrot; A F Pierre; T K Waddell; K Yasufuku; M Cypel; L G Singer Journal: Am J Transplant Date: 2015-02 Impact factor: 8.086
Authors: Deborah J Levine; Allan R Glanville; Christina Aboyoun; John Belperio; Christian Benden; Gerald J Berry; Ramsey Hachem; Don Hayes; Desley Neil; Nancy L Reinsmoen; Laurie D Snyder; Stuart Sweet; Dolly Tyan; Geert Verleden; Glen Westall; Roger D Yusen; Martin Zamora; Adriana Zeevi Journal: J Heart Lung Transplant Date: 2016-02-10 Impact factor: 10.247
Authors: L D Snyder; A L Gray; J M Reynolds; G M Arepally; A Bedoya; M G Hartwig; R D Davis; K E Lopes; W E Wegner; D F Chen; S M Palmer Journal: Am J Transplant Date: 2014-02-19 Impact factor: 8.086
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569